These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36453228)

  • 1. T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy.
    Anthony K; Ala P; Catapano F; Meng J; Domingos J; Perry M; Ricotti V; Maresh K; Phillips LC; Servais L; Seferian AM; De Lucia S; de Groot I; Krom YD; Verschuuren JGM; Niks EH; Straub V; Guglieri M; Voit T; Morgan J; Muntoni F
    Hum Gene Ther; 2023 May; 34(9-10):439-448. PubMed ID: 36453228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.
    Flanigan KM; Campbell K; Viollet L; Wang W; Gomez AM; Walker CM; Mendell JR
    Hum Gene Ther; 2013 Sep; 24(9):797-806. PubMed ID: 24010700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle.
    Ebrahimi M; Lad H; Fusto A; Tiper Y; Datye A; Nguyen CT; Jacques E; Moyle LA; Nguyen T; Musgrave B; Chávez-Madero C; Bigot A; Chen C; Turner S; Stewart BA; Pegoraro E; Vitiello L; Gilbert PM
    Acta Biomater; 2021 Sep; 132():227-244. PubMed ID: 34048976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
    Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
    Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A
    Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
    Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
    J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
    Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
    Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
    Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 18. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
    Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
    Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy.
    D'Ambrosio ES; Mendell JR
    Neurotherapeutics; 2023 Oct; 20(6):1669-1681. PubMed ID: 37673849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
    Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
    J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.